Skip to content

GRAIL, Inc. GRAL Restricted Cash

Restricted Cash at other companies

Guardant Health logo
Guardant HealthGH
$112.15M+6.5%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$4.69M+172%
Immunome logo
ImmunomeIMNM
$210K+110%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$2.71M-0.1%
Erasca, Inc. logo
Erasca, Inc.ERAS
$408K0.0%
GeneDx Holdings logo
GeneDx HoldingsWGS
$992K+0.2%

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCash.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s restricted cash?
GRAIL, Inc. (GRAL) reported restricted cash of $6.97M in Q1 2026.
How has GRAIL, Inc.'s restricted cash changed year-over-year?
GRAIL, Inc.'s restricted cash increased by 108.2% year-over-year, from $3.35M to $6.97M.
What is the long-term trend for GRAIL, Inc.'s restricted cash?
Over 2 years (2023 to 2025), GRAIL, Inc.'s restricted cash has grown at a 28.5% compound annual growth rate (CAGR), from $4.23M to $6.97M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.